Quarterly report pursuant to Section 13 or 15(d)

ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative)

v3.23.1
ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative) - Katana Pharmaceuticals Inc [Member] - Asset Purchase Agreement [Member]
$ in Millions
Dec. 22, 2020
USD ($)
Asset Acquisition [Line Items]  
Consideration paid $ 0.7
Research and development costs $ 0.7